These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 13056)

  • 1. Microbial acetylation of M factor of virginiamycin.
    De Meester C; Rondelet J
    J Antibiot (Tokyo); 1976 Dec; 29(12):1297-305. PubMed ID: 13056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Virginiamycin resistance in staphylococci (author's transl)].
    de Meester C; Rondelet J
    Pathol Biol (Paris); 1977 Dec; 25(10):685-9. PubMed ID: 418374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient adsorption of lysostaphin on bacterial cells of lysostaphin-resistant Staphylococcus aureus mutant.
    Sakurada J; Murai M; Zhijun L; Usui A; Seki K; Kobayashi K; Sumi Y; Jitsukawa H; Masuda S
    Microbiol Immunol; 1993; 37(1):29-34. PubMed ID: 8474355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of various blood culture media on lysostaphin sensitivity of staphylococci.
    Severance PJ; Kauffman CA; Sheagren JN
    J Clin Microbiol; 1980 Nov; 12(5):709-10. PubMed ID: 7276143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Resistance to streptogramin antibiotics in "Staphylococcus aureus" (author's transl)].
    Dublanchet A; Soussy CJ; Squinazi F; Duval J
    Ann Microbiol (Paris); 1977 Apr; 128A(3):277-87. PubMed ID: 411409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for streptogramin B resistance in Staphylococcus aureus by virginiamycin B lyase.
    Korczynska M; Mukhtar TA; Wright GD; Berghuis AM
    Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10388-93. PubMed ID: 17563376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of Polycations on Antibacterial Activity of Lysostaphin].
    Kulikov SN; Khairullin RZ; Varlamov VP
    Prikl Biokhim Mikrobiol; 2015; 51(6):610-5. PubMed ID: 26859963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of virginiamycin by Aureobasidium pullulans.
    Leathers TD; Rich JO; Nunnally MS; Anderson AM
    Biotechnol Lett; 2018 Jan; 40(1):157-163. PubMed ID: 29038924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of the composition of the reversion medium on the transformation of coccal forms and L-form of Staphylococcus aureus lysostaphin protoplasts].
    Kato Y; Hirachi Y; Toda Y; Kurono M; Takemasa N; Kotani S
    Osaka Daigaku Shigaku Zasshi; 1985 Dec; 30(2):296-303. PubMed ID: 3869230
    [No Abstract]   [Full Text] [Related]  

  • 10. Internally quenched peptides for the study of lysostaphin: An antimicrobial protease that kills Staphylococcus aureus.
    Warfield R; Bardelang P; Saunders H; Chan WC; Penfold C; James R; Thomas NR
    Org Biomol Chem; 2006 Oct; 4(19):3626-38. PubMed ID: 16990938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM; Kokai-Kun JF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of pH on the speed of alteration of virginiamycin factor s in aqueous medium].
    Rollmann B; Rondelet J
    Pharm Acta Helv; 1975; 50(12):455-60. PubMed ID: 3800
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on pristinamycin synergism in Staphylococcus aureus.
    Lacroix P; Aumercier M; Capmau ML; Le Goffic F
    J Antibiot (Tokyo); 1986 Sep; 39(9):1314-21. PubMed ID: 3096929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus.
    Sugai M; Fujiwara T; Ohta K; Komatsuzawa H; Ohara M; Suginaka H
    J Bacteriol; 1997 Jul; 179(13):4311-8. PubMed ID: 9209049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of lysostaphin in HeLa cells protects from host cell killing by intracellular Staphylococcus aureus.
    Klein M; Krönke M; Krut O
    Med Microbiol Immunol; 2006 Sep; 195(3):159-63. PubMed ID: 16482441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staphylococcus aureus mutants with increased lysostaphin resistance.
    Gründling A; Missiakas DM; Schneewind O
    J Bacteriol; 2006 Sep; 188(17):6286-97. PubMed ID: 16923896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro.
    Satishkumar R; Vertegel AA
    Nanotechnology; 2011 Dec; 22(50):505103. PubMed ID: 22107797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC; Foster-Frey J; Donovan DM
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electron microscopy studies of the bactericidal effects of quinupristin/dalfopristin on Staphylococcus aureus.
    Lorian V; Fernandes F
    J Antimicrob Chemother; 1999 Jun; 43(6):845. PubMed ID: 10404327
    [No Abstract]   [Full Text] [Related]  

  • 20. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic.
    Oldham ER; Daley MJ
    J Dairy Sci; 1991 Dec; 74(12):4175-82. PubMed ID: 1787188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.